At Viela, we are innovating therapies that we believe can have a meaningful impact on patients who suffer from severe and debilitating autoimmune diseases. Currently, there are over 23 million people in the U.S. alone living with autoimmune disease, however, current therapies available are rarely considered curative. Even with modern standards of care, patients may suffer from disease progression.
Our approach to drug discovery is aimed at providing targeted treatments for improved outcomes for the thousands of patients who have few or no therapeutic options.
With the Biologics License Application (BLA) for our lead asset inebilizumab accepted for review by FDA, we are currently preparing for the drug candidate’s potential commercialization. We also plan to explore its applicability in other conditions and diseases beginning with kidney desensitization later in 2019. We are also advancing VIB4920 as a potential treatment for autoimmune diseases and conditions such as Sjögren’s syndrome and kidney transplant rejection, and VIB7734 for diseases such as Sjögren’s syndrome. See our Pipeline for additional information.